Tuesday, November 4, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Bright Future Ahead for R1 RCM Analysts Predict 4694 Upside Potential

Elaine Mendonca by Elaine Mendonca
March 2, 2024
in Breaking News
0
Finances-and-tech
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Analysts are projecting a bright future for R1 RCM (NASDAQ: RCM) with an impressive upside potential of 46.94% as of March 2, 2024.

Citigroup analyst Daniel Grosslight has reiterated a Buy rating on R1 RCM and increased the price target to $16. Other analysts are also optimistic about R1 RCM, with price targets ranging from $16 to $22.

Despite a recent downgrade by Citi to Neutral with a price target of $16, there is speculation of a potential acquisition at a higher price. This has sparked expectations of a bidding war, potentially driving the share price into the “mid-to-high teens”.

Overall, the consensus among analysts is a Strong Buy for R1 RCM, with 12 buy ratings and 1 hold rating. Investors are keeping a close eye on this stock as it continues to show promise in the market.

RCM Stock Performance Shows Slight Dip on March 2, 2024: Analysis and Outlook

RCM experienced a slight dip in its stock performance on March 2, 2024. According to data from CNN Money, RCM is currently trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable over the past year and is showing positive long-term growth potential.

On March 2, 2024, RCM closed at $14.00 per share, which was a decrease of $0.05 from the previous market close. This represents a 0.36% drop in the stock price. Despite this small decline, RCM’s stock performance has been relatively steady in recent months.

After the market closed, RCM’s stock price continued to decline in after-hours trading, dropping an additional $0.21. This further decrease in the stock price may be attributed to various factors such as market volatility, investor sentiment, or company-specific news.

Investors and analysts will be closely monitoring RCM’s stock performance in the coming days to see if the downward trend continues or if the stock rebounds. It is important to consider the overall market conditions and company fundamentals when evaluating stock performance and making investment decisions.

Overall, RCM’s stock performance on March 2, 2024, reflects a slight decline but the company’s position in the healthcare industry and positive long-term growth potential may attract investors looking for stable investment opportunities.

RCM Stock Analysis: Strong Financial Performance Signals Potential Growth in 2024

On March 2, 2024, RCM stock showed promising performance based on its financial data. According to CNN Money, the company reported a total revenue of $2.25 billion for the past year, which marked a 24.79% increase compared to the previous year. Net income for RCM stood at $3.30 million for the past year, reflecting a significant increase of 105.21% compared to the previous year. Earnings per share (EPS) for RCM were reported at $0.01 for the past year, showing a 104.06% increase compared to the previous year. Overall, RCM stock showed positive growth in total revenue, net income, and EPS compared to the previous year. Despite the flat performance in the fourth quarter, the company’s strong financial performance indicates potential for future growth and profitability. Investors may want to keep an eye on RCM stock as it continues to demonstrate promising financial results.

Tags: RCM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Everi Holdings Faces Stock Decline After Downgrades from Jefferies and Truist Securities

Finances-and-tech

NCR Voyix Faces Stock Market Turbulence After Unveiling Preliminary Financial Results

COST stock news

Analysts Bullish on Veeva Systems Increase Price Target to 264

Recommended

REV Stock

REV Group Shares Hit Record High: Analyzing the Rally’s Drivers

2 months ago
Intel Stock

Intel’s Boardroom Shakeup Signals Critical Transformation Phase

2 months ago
Ocugen Stock

Ocugen’s Strategic Pivot: Betting Everything on Vision Therapies

2 months ago
Huntington Bancshares Stock

Huntington Bancshares Shares Face Investor Skepticism Despite Solid Performance

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Apple Shares Poised for Historic Quarter on Unprecedented iPhone Demand

A $7 Billion Merger Stuns Investors as Coeur Mining Shares Tumble

Tilray Shares Face Mounting Pressure Despite Earnings Beat

Microsoft’s Multi-Billion Dollar Push to Dominate the AI Landscape

Synopsys Shares Plummet Amid Fraud Allegations and Disappointing Earnings

Bloom Energy Secures Major Capital Infusion to Power Expansion

Trending

Take-Two Stock
Analysis

Wall Street Analysts Boost Take-Two Price Targets Amid Strong Gaming Performance

by Robert Sasse
November 4, 2025
0

Financial analysts are expressing renewed confidence in Take-Two Interactive, with multiple firms significantly raising their price targets...

Standard Lithium Stock

Standard Lithium Reaches Critical Milestone in Arkansas Venture

November 4, 2025
CureVac Stock

Crucial Vote Looms for CureVac Shareholders as BioNTech Acquisition Nears Finish Line

November 4, 2025
Apple Stock

Apple Shares Poised for Historic Quarter on Unprecedented iPhone Demand

November 4, 2025
Coeur Mining Stock

A $7 Billion Merger Stuns Investors as Coeur Mining Shares Tumble

November 4, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Wall Street Analysts Boost Take-Two Price Targets Amid Strong Gaming Performance
  • Standard Lithium Reaches Critical Milestone in Arkansas Venture
  • Crucial Vote Looms for CureVac Shareholders as BioNTech Acquisition Nears Finish Line

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com